948 Results

People

  1. Kris
    Kris
  2. Kelsen
    Kelsen
  3. Motzer
    Motzer
  4. O'Reilly
    O'Reilly
  5. Saltz
    Saltz
  6. Tyson
    Tyson
  7. Gralla
    Gralla
  8. Hudis
    Hudis
  9. Scher
    Scher
  10. Aghajanian
    Aghajanian

Groups

  1. Department of Medicine (633)
  2. Solid Tumor Oncology Division (507)
  3. Gastrointestinal Oncology Service (138)
  4. Survivorship Research (128)
  5. Hematologic Malignancies, Division of (127)
  6. Thoracic Oncology (112)
  7. Center for Hematologic Malignancies (109)
  8. Genitourinary Oncology Service (106)
  9. Nursing (101)
  10. Surgery (97)
  1. "vomiting"
Formats
  1. Journal Article (896)
  2. Review (27)
  3. Conference Paper (8)
  4. Editorial (6)
  5. Research Letter (4)
  6. Correspondence (2)
  7. Guidelines (2)
  8. Book Section (1)
  9. Meeting Abstract (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (633)
  2. Solid Tumor Oncology Division (507)
  3. Gastrointestinal Oncology Service (138)
  4. Survivorship Research (128)
  5. Hematologic Malignancies, Division of (127)
  6. Thoracic Oncology (112)

More Groups

People
  1. Mark Kris (70)
  2. David Kelsen (40)
  3. Robert Motzer (39)
  4. Eileen O'Reilly (30)
  5. Leonard Saltz (30)
  6. Leslie Tyson (28)

More People

Years
  1. 2025 (25)
  2. 2024 (63)
  3. 2023 (44)
  4. 2022 (32)
  5. 2021 (15)
  6. 2020 (50)

More Years

Publications
  1. Journal of Clinical Oncology (90)
  2. Cancer (47)
  3. Clinical Cancer Research (44)
  4. Lancet Oncology (38)
  5. Gynecologic Oncology (31)
  6. Cancer Treatment Reports (26)

More Publications

Publishers
  1. Elsevier Inc. (145)
  2. American Society of Clinical Oncology (92)
  3. Elsevier Science, Inc. (74)
  4. Springer (72)
  5. Oxford University Press (64)
  6. Wiley Blackwell (63)

More Publishers

Results (948)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
    Journal Article

    Coleman, R. L.; Oza, A. M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J. I.; Clamp, A.; Scambia, G.; more...
    Lancet (2017)

    Fulltext@MSK | Save
  • Androgen receptor-targeted therapy for breast cancer
    Journal Article

    Lyons, T. G.; Traina, T. A.
    Current Breast Cancer Reports (2017)

    Fulltext@MSK | Save
  • RESILIENCE: Phase III randomized, double-blind trial comparing sorafenib with capecitabine versus placebo with capecitabine in locally advanced or metastatic HER2-negative breast cancer
    Journal Article

    Baselga, J.; Zamagni, C.; Gómez, P.; Bermejo, B.; Nagai, S. E.; Melichar, B.; Chan, A.; Mángel, L.; Bergh, J.; Costa, F.; more...
    Clinical Breast Cancer (2017)

    Fulltext@MSK | Save
  • A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma
    Journal Article

    Lowery, M. A.; Yu, K. H.; Kelsen, D. P.; Harding, J. J.; Bomalaski, J. S.; Glassman, D. C.; Covington, C. M.; Brenner, R.; Hollywood, E.; Barba, A.; more...
    Cancer (2017)

    Fulltext@MSK | Save
  • Expanding the portfolio of anaplastic lymphoma kinase inhibitors for anaplastic lymphoma kinase-rearranged lung cancers
    Journal Article

    Santini, F. C.; Salhab, R. M.; Sharma, S.; Drilon, A.
    Translational Cancer Research (2017)

    Fulltext@MSK | Save
  • Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation
    Journal Article

    Momtaz, P.; Harding, J. J.; Ariyan, C.; Coit, D. G.; Merghoub, T.; Gasmi, B.; You, D.; Viale, A.; Panageas, K. S.; Samoila, A.; more...
    Oncotarget (2017)

    Fulltext@MSK | Save
  • Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma
    Journal Article

    Motzer, R. J.; Haas, N. B.; Donskov, F.; Gross-Goupil, M.; Varlamov, S.; Kopyltsov, E.; Lee, J. L.; Melichar, B.; Rini, B. I.; Choueiri, T. K.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma
    Journal Article

    Sznol, M.; Ferrucci, P. F.; Hogg, D.; Atkins, M. B.; Wolter, P.; Guidoboni, M.; Lebbé, C.; Kirkwood, J. M.; Schachter, J.; Daniels, G. A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas
    Journal Article

    Reiss, S. N.; Yerram, P.; Modelevsky, L.; Grommes, C.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma
    Journal Article

    Voss, M. H.; Hussain, A.; Vogelzang, N.; Lee, J. L.; Keam, B.; Rha, S. Y.; Vaishampayan, U.; Harris, W. B.; Richey, S.; Randall, J. M.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save